Michael Makris Questions FVIII Aurora’s Potential to Transform Hemophilia A Gene Therapy
Michael Makris, Professor of Haemostasis and Thrombosis at University of Sheffield, Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared an insightful post on LinkedIn:
“A potentially important finding was reported in a letter to the editor in today’s New England Journal of Medicine.
The authors reported a gain of function mutation in FVIII, called FVIII Aurora.
This can be thought of as analogous to FIX Padua which has transformed hemophilia B gene therapy.
Will FVIII Aurora transform hemophilia A gene therapy?
Having read the letter and the supplement, I have a number of questions/comments:
1. The thrombotic history is fairly extreme. No information about treatment with anticoagulants is given. Was this patient never treated for the multiple severe thrombotic episodes?
2. Only 2 FVIII levels are given in the supplement, and they were 370 and 615%. The patient’s clinical circumstances when these blood samples were drawn are not given. FVIII is an acute phase reactant, so knowing the status of the patient when they were drawn is critical.
3. In the letter it is stated the FVIII levels were between 300-900%. Whenever I see factor levels ending in such round numbers, I become suspicious. Did this patient really have a level that was precisely 900%? Why were the authors not asked to provide all the FVIII levels from this patient?
4. Although the patient and grandparents are deceased, we are not told if there are any other relatives with this mutation alive.
5. It is surprising that the NEJM has published this without the expression data from the recombinant variant.
Potentially this is very important, but until we see the recombinant protein expression data, we will not know how important.”
Read the full article in The New England Journal of Medicine.
Stay updated on all science in the field of bleeding disorders with Hemostasis Today.
-
Aug 16, 2025, 17:35Join the Genicular Artery Embolization (GAE) Summit!
-
Aug 16, 2025, 14:00Iron Deficiency in Polycythemia Vera: William Aird Reveals JAK2-Driven Erythropoiesis as The Key Cause
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 15, 2025, 23:31Richard Buka: Many Improvements Needed in HIT Management
-
Aug 15, 2025, 23:29Cathy Harrison: Launching A Journal Club from EAHAD and WFH
-
Aug 16, 2025, 16:33RPTH Journal: Dietmar Fries and Colleagues Explore Impact of Long-Distance Trail Running on Blood Markers
-
Aug 16, 2025, 16:15Josepha Clara Sedzro: First Cryo-EM Structure of the Coagulation Initiation Complex
-
Aug 16, 2025, 15:03Abdulla Damluji Highlights ASPREE Trial Update
-
Aug 16, 2025, 14:54Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
-
Aug 16, 2025, 13:42LMWH Use for VTE Prophylaxis in COVID-19 Hospitalized Patients - Multicenter Data from China
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman